IFNG and type 1 diabetes mellitus: Indeed, NOD mice treated with galectin-9 (gal-9) [6] to inhibit Th1 immunity are less prone to autoimmune diabetes, and blockade of intrinsic IFN-γ signaling protects NOD mice from T1D development [7, 26, 27].